Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Women Underrepresented as Oncology Trial Corresponding Authors

Key clinical point: Female corresponding authors are underrepresented among phase 3 oncology trials in the research literature.

Major finding: Among the trials in the analysis, 17.9% had female corresponding authors.

Study details: The findings are based on analysis of 598 oncologic phase 3 RCTs that tested a therapeutic intervention and were published between 2003 and 2018.

Disclosures: The authors did not note any external funding and reported having no disclosures.


Ludmir EB et al. JAMA Oncol. 2019 Aug 8. doi: 10.1001/jamaoncol.2019.2196.